

# Walter

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7498857/publications.pdf>

Version: 2024-02-01

211  
papers

18,189  
citations

12303

69  
h-index

14156

128  
g-index

215  
all docs

215  
docs citations

215  
times ranked

10604  
citing authors

#	ARTICLE	IF	CITATIONS
1	DSM-5 Criteria for Substance Use Disorders: Recommendations and Rationale. <i>American Journal of Psychiatry</i> , 2013, 170, 834-851.	4.0	1,113
2	The Clinical Opiate Withdrawal Scale (COWS). <i>Journal of Psychoactive Drugs</i> , 2003, 35, 253-259.	1.0	832
3	Validation of the alcohol, smoking and substance involvement screening test (ASSIST). <i>Addiction</i> , 2008, 103, 1039-1047.	1.7	825
4	Structural Abnormalities in the Brains of Human Subjects Who Use Methamphetamine. <i>Journal of Neuroscience</i> , 2004, 24, 6028-6036.	1.7	671
5	Office-Based Treatment of Opiate Addiction with a Sublingual-Tablet Formulation of Buprenorphine and Naloxone. <i>New England Journal of Medicine</i> , 2003, 349, 949-958.	13.9	531
6	Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid Dependence. <i>Archives of General Psychiatry</i> , 2011, 68, 1238.	13.8	463
7	Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. <i>Lancet, The</i> , 2011, 377, 1506-1513.	6.3	451
8	Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. <i>Addiction</i> , 1998, 93, 475-486.	1.7	350
9	Mood Disturbances and Regional Cerebral Metabolic Abnormalities in Recently Abstinent Methamphetamine Abusers. <i>Archives of General Psychiatry</i> , 2004, 61, 73.	13.8	346
10	Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. <i>Addiction</i> , 2014, 109, 79-87.	1.7	345
11	A Controlled Trial Comparing Buprenorphine and Methadone Maintenance in Opioid Dependence. <i>Archives of General Psychiatry</i> , 1996, 53, 401.	13.8	330
12	Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent. <i>Drug and Alcohol Dependence</i> , 2001, 63, 139-146.	1.6	290
13	Cognitive Impairment in Individuals Currently Using Methamphetamine. <i>American Journal on Addictions</i> , 2000, 9, 222-231.	1.3	274
14	Hyperalgesic responses in methadone maintenance patients. <i>Pain</i> , 2001, 90, 91-96.	2.0	272
15	A Comparison of Contingency Management and Cognitive-Behavioral Approaches During Methadone Maintenance Treatment for Cocaine Dependence. <i>Archives of General Psychiatry</i> , 2002, 59, 817.	13.8	259
16	A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid, detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. <i>Addiction</i> , 2005, 100, 1090-1100.	1.7	213
17	Smoking cessation in methadone maintenance. <i>Addiction</i> , 2002, 97, 1317-1328.	1.7	212
18	Long-Term Course of Opioid Addiction. <i>Harvard Review of Psychiatry</i> , 2015, 23, 76-89.	0.9	212

#	ARTICLE	IF	CITATIONS
19	Comparative Profiles of Men and Women with Opioid Dependence: Results from a National Multisite Effectiveness Trial. <i>American Journal of Drug and Alcohol Abuse</i> , 2011, 37, 313-323.	1.1	205
20	Randomized Placebo-Controlled Trial of Baclofen for Cocaine Dependence. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 1440-1448.	1.1	204
21	A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. <i>Addiction</i> , 2006, 101, 267-274.	1.7	199
22	Methadyl Acetate and Methadone as Maintenance Treatments for Heroin Addicts. <i>Archives of General Psychiatry</i> , 1976, 33, 709.	13.8	195
23	Bupropion for the Treatment of Methamphetamine Dependence. <i>Neuropsychopharmacology</i> , 2008, 33, 1162-1170.	2.8	194
24	Cognitive Performance of Current Methamphetamine and Cocaine Abusers. <i>Journal of Addictive Diseases</i> , 2001, 21, 61-74.	0.8	193
25	Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 778-790.	6.3	191
26	Methamphetamine Abstinence Syndrome: Preliminary Findings. <i>American Journal on Addictions</i> , 2004, 13, 248-255.	1.3	180
27	An intensive outpatient approach for cocaine abuse treatment. <i>Journal of Substance Abuse Treatment</i> , 1995, 12, 117-127.	1.5	175
28	Sexual HIV risk among gay and bisexual male methamphetamine abusers. <i>Journal of Substance Abuse Treatment</i> , 1996, 13, 483-486.	1.5	170
29	Pain Responses in Methadone-Maintained Opioid Abusers. <i>Journal of Pain and Symptom Management</i> , 2000, 20, 237-245.	0.6	170
30	Will the Methamphetamine Problem Go Away?. <i>Journal of Addictive Diseases</i> , 2001, 21, 5-19.	0.8	169
31	A randomized controlled trial of a brief intervention for illicit drugs linked to the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) in clients recruited from primary health care settings in four countries. <i>Addiction</i> , 2012, 107, 957-966.	1.7	167
32	Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multisite trial. <i>Addiction</i> , 2016, 111, 695-705.	1.7	165
33	A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. <i>Drug and Alcohol Dependence</i> , 1995, 40, 125-131.	1.6	164
34	Medications development: Successes and challenges. , 2005, 108, 94-108.		154
35	Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. <i>Pain</i> , 2001, 93, 155-163.	2.0	149
36	Buprenorphine Implants for Treatment of Opioid Dependence. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 1576.	3.8	149

#	ARTICLE	IF	CITATIONS
37	Correspondence. Neuropsychopharmacology, 1998, 18, 403-404.	2.8	140
38	Prescription opioid abuse, pain and addiction: Clinical issues and implications. Drug and Alcohol Review, 2011, 30, 300-305.	1.1	138
39	Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug and Alcohol Dependence, 2008, 96, 222-232.	1.6	132
40	The effect of relapse on cognition in abstinent methamphetamine abusers. Journal of Substance Abuse Treatment, 2004, 27, 59-66.	1.5	131
41	Bringing Buprenorphine-Naloxone Detoxification to Community Treatment Providers: The NIDA Clinical Trials Network Field Experience. American Journal on Addictions, 2004, 13, S42-S66.	1.3	130
42	Substitution Pharmacotherapies for Opioid Addiction: From Methadone to LAAM and Buprenorphine. Journal of Psychoactive Drugs, 1994, 26, 119-128.	1.0	127
43	Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug and Alcohol Dependence, 2006, 85, 12-18.	1.6	126
44	A Comparison of Patterns of Methamphetamine and Cocaine Use. Journal of Addictive Diseases, 2001, 21, 35-44.	0.8	122
45	Cerebral Metabolic Dysfunction and Impaired Vigilance in Recently Abstinent Methamphetamine Abusers. Biological Psychiatry, 2005, 58, 770-778.	0.7	121
46	Bupropion Hydrochloride versus Placebo, in Combination with Cognitive Behavioral Therapy, for the Treatment of Cocaine Abuse/Dependence. Journal of Addictive Diseases, 2008, 27, 13-23.	0.8	112
47	Clinical efficacy of buprenorphine: comparisons to methadone and placebo. Drug and Alcohol Dependence, 2003, 70, S49-S57.	1.6	110
48	Contingency management for tobacco smoking in methadone-maintained opiate addicts. Addictive Behaviors, 1996, 21, 409-412.	1.7	105
49	Buprenorphine tapering schedule and illicit opioid use. Addiction, 2009, 104, 256-265.	1.7	103
50	Methamphetamine and Cocaine Users: Differences in Characteristics and Treatment Retention. Journal of Psychoactive Drugs, 2000, 32, 233-238.	1.0	101
51	Methamphetamine: drug use and psychoses becomes a major public health issue in the Asia Pacific region. Addiction, 2002, 97, 771-772.	1.7	101
52	Buprenorphine/Naloxone and Methadone Maintenance Treatment Outcomes for Opioid Analgesic, Heroin, and Combined Users: Findings From Starting Treatment With Agonist Replacement Therapies (START). Journal of Studies on Alcohol and Drugs, 2013, 74, 605-613.	0.6	100
53	Comparison of behavioral treatment conditions in buprenorphine maintenance. Addiction, 2013, 108, 1788-1798.	1.7	99
54	Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction, 2013, 108, 1628-1637.	1.7	98

#	ARTICLE	IF	CITATIONS
55	Quantitative EEG abnormalities in recently abstinent methamphetamine dependent individuals. <i>Clinical Neurophysiology</i> , 2003, 114, 410-415.	0.7	96
56	Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: A randomized trial. <i>Drug and Alcohol Dependence</i> , 2013, 128, 71-76.	1.6	94
57	Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. <i>Drug and Alcohol Dependence</i> , 2006, 85, 177-184.	1.6	91
58	Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. <i>Drug and Alcohol Dependence</i> , 2010, 109, 20-29.	1.6	91
59	Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts. <i>Drug and Alcohol Dependence</i> , 1997, 45, 131-134.	1.6	90
60	Traditional Medicine in the Treatment of Drug Addiction. <i>American Journal of Drug and Alcohol Abuse</i> , 2009, 35, 1-11.	1.1	90
61	Hyperalgesia in Heroin Dependent Patients and the Effects of Opioid Substitution Therapy. <i>Journal of Pain</i> , 2012, 13, 401-409.	0.7	87
62	Diagnosing Addictive Disease in Chronic Pain Patients. <i>Psychosomatics</i> , 1996, 37, 223-235.	2.5	81
63	Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone. <i>Addiction</i> , 2013, 108, 2141-2149.	1.7	81
64	Naltrexone and Dysphoria: Fact or Myth?. <i>American Journal on Addictions</i> , 2002, 11, 151-160.	1.3	78
65	Methadone maintenance patients are cross-tolerant to the antinociceptive effects of very high plasma morphine concentrations. <i>Pain</i> , 2006, 120, 267-275.	2.0	78
66	HIV Risk Reduction With Buprenorphine+Naloxone or Methadone. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 288-293.	0.9	77
67	A Cooperative Clinical Study of Methadyl Acetate. <i>Archives of General Psychiatry</i> , 1978, 35, 345.	13.8	76
68	Patient Perspectives on Buprenorphine/Naloxone: A Qualitative Study of Retention During the Starting Treatment with Agonist Replacement Therapies (START) Study. <i>Journal of Psychoactive Drugs</i> , 2014, 46, 412-426.	1.0	75
69	An Intronic Variant in OPRD1 Predicts Treatment Outcome for Opioid Dependence in African-Americans. <i>Neuropsychopharmacology</i> , 2013, 38, 2003-2010.	2.8	74
70	Magnetic resonance imaging evidence of "silent" cerebrovascular toxicity in cocaine dependence. <i>Biological Psychiatry</i> , 1999, 45, 1203-1211.	0.7	73
71	A Comparison of Injecting and Noninjecting Methamphetamine Users. <i>Journal of Psychoactive Drugs</i> , 2000, 32, 229-232.	1.0	70
72	Status of Methamphetamine Users 5 Years After Outpatient Treatment. <i>Journal of Addictive Diseases</i> , 2001, 21, 107-119.	0.8	70

#	ARTICLE	IF	CITATIONS
73	A multi-site, two-phase, Prescription Opioid Addiction Treatment Study (POATS): Rationale, design, and methodology. <i>Contemporary Clinical Trials</i> , 2010, 31, 189-199.	0.8	67
74	Interest in Smoking Cessation Among Methadone Maintained Outpatients. <i>Journal of Addictive Diseases</i> , 1998, 17, 9-19.	0.8	64
75	Gabapentin improves cold-pressor pain responses in methadone-maintained patients. <i>Drug and Alcohol Dependence</i> , 2010, 109, 213-219.	1.6	64
76	A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal†. <i>Drug and Alcohol Dependence</i> , 2008, 97, 158-168.	1.6	63
77	Treatment for amphetamine withdrawal. <i>The Cochrane Library</i> , 2009, , CD003021.	1.5	63
78	Buprenorphine: blending practice and research. <i>Journal of Substance Abuse Treatment</i> , 2002, 23, 87-92.	1.5	61
79	Risperidone pre-treatment reduces the euphoric effects of experimentally administered cocaine. <i>Psychiatry Research</i> , 2001, 102, 227-233.	1.7	59
80	Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine+naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence. <i>Drug and Alcohol Dependence</i> , 2009, 99, 28-36.	1.6	59
81	Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder. <i>Addiction</i> , 2014, 109, 1489-1500.	1.7	59
82	Randomized Controlled Trials of the D1/D5 Antagonist Ecopipam for Weight Loss in Obese Subjects. <i>Obesity</i> , 2007, 15, 1717-1731.	1.5	56
83	Effectiveness of drug dependence treatment in HIV prevention. <i>International Journal of Drug Policy</i> , 2005, 16, 67-75.	1.6	55
84	Management of methamphetamine abuse and dependence. <i>Current Psychiatry Reports</i> , 2006, 8, 345-354.	2.1	54
85	Distinctive Trajectories of Opioid Use Over an Extended Follow-up of Patients in a Multisite Trial on Buprenorphine+S+Naloxone and Methadone. <i>Journal of Addiction Medicine</i> , 2017, 11, 63-69.	1.4	54
86	Association between quantitative EEG and neurocognition in methamphetamine-dependent volunteers. <i>Clinical Neurophysiology</i> , 2004, 115, 194-198.	0.7	53
87	Buprenorphine+Analoxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study. <i>Addiction</i> , 2016, 111, 1416-1427.	1.7	53
88	Cognitive Deficits Among Methamphetamine Users with Attention Deficit Hyperactivity Disorder Symptomatology. <i>Journal of Addictive Diseases</i> , 2001, 21, 75-89.	0.8	51
89	A screening trial of amantadine as a medication for cocaine dependence. <i>Drug and Alcohol Dependence</i> , 2002, 66, 217-224.	1.6	50
90	Cocaine abuse treatment: A review of current strategies. <i>Journal of Substance Abuse</i> , 1991, 3, 457-491.	1.1	49

#	ARTICLE	IF	CITATIONS
91	NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale. <i>Contemporary Clinical Trials</i> , 2016, 50, 253-264.	0.8	49
92	Cocaine Infusion Increases Interferon- $\gamma$ and Decreases Interleukin-10 in Cocaine-Dependent Subjects. <i>Clinical Immunology and Immunopathology</i> , 1998, 89, 181-190.	2.1	47
93	Neurobehavioral Treatment for Cocaine Dependency. <i>Journal of Psychoactive Drugs</i> , 1990, 22, 159-171.	1.0	45
94	From research to the real world: Buprenorphine in the decade of the Clinical Trials Network. <i>Journal of Substance Abuse Treatment</i> , 2010, 38, S53-S60.	1.5	45
95	Integrating treatments for methamphetamine abuse: A psychosocial perspective. <i>Journal of Addictive Diseases</i> , 1997, 16, 41-50.	0.8	44
96	Buprenorphine pharmacotherapy and behavioral treatment: Comparison of outcomes among prescription opioid users, heroin users and combination users. <i>Journal of Substance Abuse Treatment</i> , 2015, 48, 70-76.	1.5	44
97	Depressive Symptoms, Substance Use, and HIV-Related High-Risk Behaviors Among Opioid-Dependent Individuals: Results From the Clinical Trials Network. <i>Substance Use and Misuse</i> , 2011, 46, 1716-1725.	0.7	42
98	Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine. <i>Drug and Alcohol Dependence</i> , 2006, 82, 25-31.	1.6	41
99	Selegiline Effects on Cocaine-Induced Changes in Medial Temporal Lobe Metabolism and Subjective Ratings of Euphoria. <i>Neuropsychopharmacology</i> , 1999, 20, 582-590.	2.8	39
100	Addiction Pharmacotherapy 2000: New Options, New Challenges. <i>Journal of Psychoactive Drugs</i> , 2000, 32, 371-378.	1.0	39
101	Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX). <i>Journal of Addiction Medicine</i> , 2015, 9, 238-243.	1.4	39
102	Use of item response theory and latent class analysis to link poly-substance use disorders with addiction severity, HIV risk, and quality of life among opioid-dependent patients in the Clinical Trials Network. <i>Drug and Alcohol Dependence</i> , 2011, 118, 186-193.	1.6	38
103	Prescription of opioids for treatment of pain in patients with addictive disease. <i>Journal of Pain and Symptom Management</i> , 1993, 8, 289-296.	0.6	37
104	A Comparison of Buprenorphine Taper Outcomes Between Prescription Opioid and Heroin Users. <i>Journal of Addiction Medicine</i> , 2013, 7, 33-38.	1.4	37
105	Effect of oral ketorolac and gender on human cold pressor pain tolerance. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2003, 30, 759-763.	0.9	36
106	Pain and continued opioid use in individuals receiving buprenorphine-naloxone for opioid detoxification: Secondary analyses from the Clinical Trials Network. <i>Journal of Substance Abuse Treatment</i> , 2010, 38, S80-S86.	1.5	36
107	Medication-assisted treatment for opioid addiction: Methadone and buprenorphine. <i>Journal of Food and Drug Analysis</i> , 2013, 21, S69-S72.	0.9	36
108	Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST). <i>Addiction</i> , 2005, 100, 78-90.	1.7	35

#	ARTICLE	IF	CITATIONS
109	Comparison of Buprenorphine Treatment for Opioid Dependence in 3 Settings. <i>Journal of Addiction Medicine</i> , 2012, 6, 68-76.	1.4	35
110	Pain volatility and prescription opioid addiction treatment outcomes in patients with chronic pain.. <i>Experimental and Clinical Psychopharmacology</i> , 2015, 23, 428-435.	1.3	35
111	Testing and linkage to HIV care in China: a cluster-randomised trial. <i>Lancet HIV</i> , 2017, 4, e555-e565.	2.1	35
112	Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: A long-term study. <i>Journal of Substance Abuse Treatment</i> , 2020, 110, 1-8.	1.5	35
113	Depressive Illness in Childhood Presenting as Severe Headache. <i>JAMA Pediatrics</i> , 1970, 120, 122.	3.6	34
114	The Treatment Effectiveness Assessment (TEA): an efficient, patient-centered instrument for evaluating progress in recovery from addiction. <i>Substance Abuse and Rehabilitation</i> , 2012, 3, 129.	1.6	34
115	Pharmacistsâ€™ and Techniciansâ€™ Perceptions and Attitudes Toward Dispensing Buprenorphine/Naloxone to Patients with Opioid Dependence. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2005, 45, 23-32.	0.7	33
116	Treatment for amphetamine psychosis. <i>The Cochrane Library</i> , 2009, , CD003026.	1.5	33
117	Efficacy of Cognitive Behavioral Therapy on Opiate Use and Retention in Methadone Maintenance Treatment in China: A Randomised Trial. <i>PLoS ONE</i> , 2015, 10, e0127598.	1.1	32
118	Psychological Approaches for the Treatment of Cocaine Dependence-A Neurobehavioral Approach. <i>Journal of Addictive Diseases</i> , 1992, 11, 97-119.	0.8	31
119	A 3-year progress report on the implementation of LAAM in the United States. <i>Addiction</i> , 1998, 93, 533-540.	1.7	31
120	Use of methamphetamine by young people: is there reason for concern?. <i>Addiction</i> , 2007, 102, 1021-1022.	1.7	31
121	&lt;p&gt;Depot Buprenorphine Injection In The Management Of Opioid Use Disorder: From Development To Implementation&lt;/p&gt;. <i>Substance Abuse and Rehabilitation</i> , 2019, Volume 10, 69-78.	1.6	31
122	Cocaine Abuse Among Methadone Maintenance Patients: Are There Effective Treatment Strategies?. <i>Journal of Psychoactive Drugs</i> , 1994, 26, 129-136.	1.0	30
123	Buprenorphine for opioid dependence. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 609-616.	1.4	30
124	Ultrafiltration Using the Amicon MPS-1 for Assessing Methadone Plasma Protein Binding. <i>Therapeutic Drug Monitoring</i> , 1997, 19, 83-87.	1.0	30
125	Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study. <i>Journal of Addiction Medicine</i> , 2019, 13, 442-449.	1.4	30
126	Use of Disulfiram for Alcoholics in Methadone Maintenance Programs. <i>Archives of General Psychiatry</i> , 1983, 40, 851.	13.8	29



#	ARTICLE	IF	CITATIONS
127	Dancing with strangers. <i>Addictive Behaviors</i> , 2002, 27, 941-949.	1.7	29
128	Irritability following abstinence from cocaine predicts euphoric effects of cocaine administration. <i>Addictive Behaviors</i> , 2003, 28, 817-821.	1.7	29
129	Opiate Recidivism in a Drug-Treatment Program: Comparison of Hair and Urine Data. <i>Journal of Analytical Toxicology</i> , 2003, 27, 412-428.	1.7	28
130	Opioid effects and opioid withdrawal during a 24 h dosing interval in patients maintained on buprenorphine. <i>Drug and Alcohol Dependence</i> , 2003, 69, 317-322.	1.6	27
131	Participant Characteristics and Buprenorphine Dose. <i>American Journal of Drug and Alcohol Abuse</i> , 2011, 37, 453-459.	1.1	27
132	Buprenorphine implant for opioid addiction. <i>Pain Management</i> , 2012, 2, 345-350.	0.7	27
133	Health-related quality of life changes associated with buprenorphine treatment for opioid dependence. <i>Quality of Life Research</i> , 2012, 21, 1177-1183.	1.5	27
134	Participants Receiving Dehydroepiandrosterone During Treatment for Cocaine Dependence Show High Rates of Cocaine Use in a Placebo-Controlled Pilot Study.. <i>Experimental and Clinical Psychopharmacology</i> , 2004, 12, 126-135.	1.3	26
135	CLINICAL STUDY: Lack of effect of chronic dextromethorphan on experimental pain tolerance in methadone-maintained patients. <i>Addiction Biology</i> , 2008, 13, 393-402.	1.4	26
136	Cochrane systematic reviews in the field of addiction: What's there and what should be. <i>Drug and Alcohol Dependence</i> , 2011, 113, 96-103.	1.6	26
137	Predictors of outcome after short-term stabilization with buprenorphine. <i>Journal of Substance Abuse Treatment</i> , 2013, 44, 336-342.	1.5	26
138	Differences in regional brain metabolism associated with marijuana abuse in methamphetamine abusers. <i>Synapse</i> , 2005, 57, 113-115.	0.6	25
139	Multisite effectiveness trials of treatments for substance abuse and co-occurring problems: Have we chosen the best designs?. <i>Journal of Substance Abuse Treatment</i> , 2010, 38, S97-S112.	1.5	24
140	Double-blind placebo-controlled evaluation of the PROMETA protocol for methamphetamine dependence. <i>Addiction</i> , 2012, 107, 361-369.	1.7	24
141	Using behavioral economics to predict opioid use during prescription opioid dependence treatment. <i>Drug and Alcohol Dependence</i> , 2015, 148, 62-68.	1.6	24
142	The CSAT Methamphetamine Treatment Program: Research Design Accommodations for "Real World" Application. <i>Journal of Psychoactive Drugs</i> , 2000, 32, 149-156.	1.0	23
143	Buprenorphine as a Pharmacotherapy for Cocaine Abuse.. <i>Journal of Addictive Diseases</i> , 1995, 14, 97-114.	0.8	22
144	Injectable extended-release naltrexone for opioid dependence. <i>Lancet</i> , The, 2011, 378, 665.	6.3	22

#	ARTICLE	IF	CITATIONS
145	Cocaine Use Reduction with Buprenorphine (CURB): Rationale, design, and methodology. <i>Contemporary Clinical Trials</i> , 2013, 34, 196-204.	0.8	22
146	Comparing buprenorphine induction experience with heroin and prescription opioid users. <i>Journal of Substance Abuse Treatment</i> , 2012, 43, 285-290.	1.5	21
147	Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction. <i>Addiction</i> , 2017, 112, 1202-1209.	1.7	21
148	Patient perspectives of opiate withdrawal. <i>Drug and Alcohol Dependence</i> , 1983, 12, 167-172.	1.6	20
149	Effects of selegiline pretreatment on response to experimental cocaine administration. <i>Psychiatry Research</i> , 1999, 87, 101-106.	1.7	20
150	Integration of research in pharmacotherapy for addictive disease: Where are we? Where are we going?. <i>Journal of Addictive Diseases</i> , 1997, 16, 83-102.	0.8	18
151	Buprenorphine 101. <i>Journal of Addictive Diseases</i> , 2007, 26, 93-99.	0.8	18
152	Alcohol and drug dependence symptom items as brief screeners for substance use disorders: Results from the Clinical Trials Network. <i>Journal of Psychiatric Research</i> , 2012, 46, 360-369.	1.5	18
153	United Nations Office on Drugs and Crime International Network of Drug Dependence Treatment and Rehabilitation Resource Centres: Treatnet. <i>Substance Abuse</i> , 2010, 31, 251-263.	1.1	17
154	Sex differences in opioid use and medical issues during buprenorphine/naloxone treatment. <i>American Journal of Drug and Alcohol Abuse</i> , 2018, 44, 488-496.	1.1	17
155	Thin-layer Chromatography and Enzyme Immunoassay of L-Alpha-Acetyl Methadol and Methadone Metabolites in Urine. <i>Clinical Chemistry</i> , 1975, 21, 109-112.	1.5	16
156	New trends in opiate pharmacotherapy. <i>Drug and Alcohol Review</i> , 2001, 20, 79-94.	1.1	16
157	Health Conditions in Methamphetamine-Dependent Adults 3 Years After Treatment. <i>Journal of Addiction Medicine</i> , 2009, 3, 155-163.	1.4	16
158	Restabilization With Methadone After Methadyl Acetate Maintenance. <i>Archives of General Psychiatry</i> , 1980, 37, 194.	13.8	15
159	Recent advances in the treatment of opiate addiction. <i>Clinical Neuroscience Research</i> , 2005, 5, 161-167.	0.8	15
160	The NIDA Methamphetamine Clinical Trials Group: a strategy to increase clinical trials research capacity. <i>Addiction</i> , 2007, 102, 107-113.	1.7	15
161	Association of Race and Ethnicity With Withdrawal Symptoms, Attrition, Opioid Use, and Side-Effects During Buprenorphine Therapy. <i>Journal of Ethnicity in Substance Abuse</i> , 2010, 9, 106-114.	0.6	15
162	The relationship between primary prescription opioid and buprenorphine-naloxone induction outcomes in a prescription opioid dependent sample. <i>American Journal on Addictions</i> , 2014, 23, 343-348.	1.3	15

#	ARTICLE	IF	CITATIONS
163	Remission from chronic opioid use—Studying environmental and socio-economic factors on recovery (RECOVER): Study design and participant characteristics. <i>Contemporary Clinical Trials</i> , 2019, 76, 93-103.	0.8	15
164	Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder. <i>Journal of Addiction Medicine</i> , 2016, 10, 236-243.	1.4	14
165	Conducting Clinical Research with Prescription Opioid Dependence: Defining the Population. <i>American Journal on Addictions</i> , 2010, 19, 141-146.	1.3	13
166	Loss to Follow-Up from HIV Screening to ART Initiation in Rural China. <i>PLoS ONE</i> , 2016, 11, e0164346.	1.1	13
167	A Cooperative Clinical Study of Methadyl Acetate. <i>Archives of General Psychiatry</i> , 1980, 37, 908.	13.8	12
168	Clinical Pharmacokinetics of Lofexidine, the $\mu$ -2-Adrenergic Receptor Agonist, in Opiate Addicts Plasma Using a Highly Sensitive Liquid Chromatography Tandem Mass Spectrometric Analysis. <i>American Journal of Drug and Alcohol Abuse</i> , 2008, 34, 611-616.	1.1	12
169	Opioid Addiction Treatment Modalities and Some Guidelines to Their Optimal Use. <i>Journal of Psychoactive Drugs</i> , 1991, 23, 151-163.	1.0	11
170	Buprenorphine as a Pharmacotherapy for Opiate Addiction What Dose Provides a Therapeutic Response?. <i>American Journal on Addictions</i> , 1996, 5, 220-230.	1.3	11
171	Neuropsychological and Diagnostic Differences Between Recidivistically Violent Not Criminally Responsible and Mentally Ill Prisoners. <i>International Journal of Law and Psychiatry</i> , 2000, 23, 161-172.	0.5	11
172	Variation in Neurophysiological Function and Evidence of Quantitative Electroencephalogram Discordance: Predicting Cocaine-Dependent Treatment Attrition. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2006, 18, 208-216.	0.9	11
173	Advances in Opioid Antagonist Treatment for Opioid Addiction. <i>Psychiatric Clinics of North America</i> , 2012, 35, 297-308.	0.7	11
174	If a US Drug Abuse Epidemic Fails to Include a Major East Coast City, Can It Be Called an Epidemic?. <i>Journal of Addictive Diseases</i> , 2001, 21, 1-4.	0.8	10
175	Injectable pharmacotherapy for opioid use disorders (IPOD). <i>Contemporary Clinical Trials</i> , 2016, 49, 70-77.	0.8	10
176	Measuring recovery in opioid use disorder: clinical utility and psychometric properties of the Treatment Effectiveness Assessment. <i>Substance Abuse and Rehabilitation</i> , 2019, Volume 10, 13-21.	1.6	10
177	Pharmacokinetics of Buprenorphine: A Comparison of Sublingual Tablet Versus Liquid after Chronic Dosing. <i>Journal of Addiction Medicine</i> , 2007, 1, 88-95.	1.4	9
178	Comparisons of Analgesic Potency and Side Effects of Buprenorphine and Buprenorphine With Ultra-low-dose Naloxone. <i>Journal of Addiction Medicine</i> , 2012, 6, 118-123.	1.4	9
179	A Perspective on Opioid Pharmacotherapy: Where We Are and How We Got Here. <i>Journal of NeuroImmune Pharmacology</i> , 2016, 11, 394-400.	2.1	9
180	Integration of Research in Pharmacotherapy for Addictive Disease:. <i>Journal of Addictive Diseases</i> , 1997, 16, 83-102.	0.8	8

#	ARTICLE	IF	CITATIONS
181	Apathy predicts hedonic but not craving response to cocaine. <i>Pharmacology Biochemistry and Behavior</i> , 2005, 82, 236-240.	1.3	7
182	Provision of Ancillary Medications During Buprenorphine Detoxification Does Not Improve Treatment Outcomes. <i>Journal of Addictive Diseases</i> , 2010, 29, 23-29.	0.8	7
183	HIV/AIDS and Drug Use in China—Interactions, Impacts, and Issues. <i>Substance Use and Misuse</i> , 2012, 47, 1015-1025.	0.7	7
184	Medication-assisted therapy for opioid addiction. <i>Journal of Food and Drug Analysis</i> , 2013, 21, S13-S15.	0.9	7
185	Dose, Plasma Level, and Treatment Outcome Among Methadone Patients in Shanghai, China. <i>Neuroscience Bulletin</i> , 2016, 32, 538-544.	1.5	7
186	Current Status of the Evaluation of LAAM as a Maintenance Drug for Heroin Addicts. <i>American Journal of Drug and Alcohol Abuse</i> , 1975, 2, 307-315.	1.1	6
187	Diffusion of Substance Abuse Treatment: Will Buprenorphine be a Success?. <i>Journal of Psychoactive Drugs</i> , 2004, 36, 115-117.	1.0	6
188	Prescription opioid addiction and chronic pain: More than a feeling. <i>Drug and Alcohol Dependence</i> , 2017, 173, S73-S74.	1.6	6
189	Outcome Study: Comparison of Short-Term vs Long-Term Treatment in a Residential Community. <i>Substance Use and Misuse</i> , 1991, 27, 15-23.	0.6	5
190	Urine Toxicology as an Outcome Measure in Drug Abuse Clinical Trials. <i>Journal of Addictive Diseases</i> , 1996, 15, 85-92.	0.8	5
191	Cynthia's Dilemma. <i>American Journal of Bioethics</i> , 2002, 2, 55-56.	0.5	5
192	Central Retinal Artery Occlusion in Sydenham's Chorea. <i>JAMA Pediatrics</i> , 1969, 118, 525.	3.6	4
193	Alternative Induction and Crossover Schedules for Methadyl Acetate. <i>Archives of General Psychiatry</i> , 1984, 41, 193.	13.8	4
194	<p><p>An Updated Version of the Treatment Effectiveness Assessment (TEA) [Letter]</p></p>. <i>Substance Abuse and Rehabilitation</i> , 2020, Volume 11, 21-22.	1.6	4
195	Substance Abuse: Sedative, Hypnotic, or Anxiolytic Use Disorders. , 0, , 1186-1200.		4
196	Women on LAAM Maintenance: Initial Experiences. <i>Journal of Psychedelic Drugs</i> , 1979, 11, 223-229.	0.3	3
197	Medications in the Treatment of Addictive Disease. <i>Journal of Psychoactive Drugs</i> , 1991, 23, 365-370.	1.0	3
198	Substance use and treatment options in Cambodia. <i>Drug and Alcohol Review</i> , 2004, 23, 365-367.	1.1	3

#	ARTICLE	IF	CITATIONS
199	Urine and Plasma Pharmacokinetics of Lofexidine after Oral Delivery in Opiate-Dependent Patients. American Journal of Drug and Alcohol Abuse, 2009, 35, 311-315.	1.1	3
200	DSM-V: TIME FOR CHANGE. Addiction, 2011, 106, 872-873.	1.7	3
201	Examining the factor structure of the Clinical Opiate Withdrawal Scale: A secondary data analysis from the National Drug Abuse Treatment Clinical Trials Network (CTN) 0003. Drug and Alcohol Dependence, 2015, 152, 218-223.	1.6	3
202	Care cascade structural intervention versus standard of care in the diagnosis and treatment of HIV in China: a cluster-randomized controlled trial protocol. BMC Health Services Research, 2017, 17, 397.	0.9	3
203	LONG-SUFFERING OR PROLONGED SUFFERING? TIME MATTERS. Addiction, 2009, 104, 1429-1430.	1.7	2
204	A Clinical Physiologic Correlate of Voluntary Gaze Palsy, Optokinetic Nystagmus, and Vestibular Nystagmus. American Journal of Ophthalmology, 1970, 69, 437-439.	1.7	1
205	Buprenorphine for opioid addiction. Neuropsychiatry, 2013, 3, 535-543.	0.4	1
206	Prescription drug overdose: between patients and their doctors. Substance Abuse and Rehabilitation, 2013, 4, 1.	1.6	1
207	The Treatment Effectiveness Assessment (TEA). Substance Abuse and Rehabilitation, 2013, 4, 73.	1.6	1
208	Buprenorphine Maintenance Subjects Are Hyperalgesic and Have No Antinociceptive Response to a Very High Morphine Dose. Pain Medicine, 2020, 21, 2007-2008.	0.9	1
209	[Commentary] WHY WE DO WHAT WE DOâ€”DELIVERY OF BUPRENORPHINE AND THE TREATMENT OF OPIOID ADDICTION. Addiction, 2007, 102, 1908-1909.	1.7	0
210	Commentary on Brooner et al. (2013): One-stop shopping-what sells and what doesn't. Addiction, 2013, 108, 1952-1953.	1.7	0
211	In memoriamâ€”C. James Klett, Ph.D. Neuropsychopharmacology, 2021, 46, 1060-1060.	2.8	0